HERON THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.44 USD | +1.18% |
|
+22.42% | +102.35% |
| May. 15 | Transcript : Heron Therapeutics, Inc. - Analyst/Investor Day | |
| May. 07 | Transcript : Heron Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,116 | 1,923 | 930.7 | 297.2 | 255.1 | 518.2 | - | - |
| Enterprise Value (EV) 1 | 2,116 | 1,923 | 930.7 | 297.2 | 255.1 | 518.2 | 518.2 | 518.2 |
| P/E ratio | -9.4 x | -8.47 x | -4.08 x | -1.5 x | -2.13 x | -38.2 x | 516 x | 14.3 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 14.5 x | 21.7 x | 10.8 x | 2.76 x | 2.01 x | 3.51 x | 2.91 x | 2.39 x |
| EV / Revenue | 14.5 x | 21.7 x | 10.8 x | 2.76 x | 2.01 x | 3.51 x | 2.91 x | 2.39 x |
| EV / EBITDA | - | -8,534,465 x | - | - | - | - | - | - |
| EV / FCF | -16.1 x | -10 x | -4.51 x | -2 x | - | -15.8 x | -85 x | 17.9 x |
| FCF Yield | -6.22% | -9.97% | -22.2% | -50% | - | -6.33% | -1.18% | 5.6% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 90,051 | 90,855 | 101,935 | 118,888 | 150,073 | 150,653 | - | - |
| Reference price 2 | 23.50 | 21.16 | 9.130 | 2.500 | 1.700 | 3.440 | 3.440 | 3.440 |
| Announcement Date | 3/2/20 | 2/24/21 | 2/28/22 | 3/23/23 | 3/12/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 146 | 88.64 | 86.35 | 107.7 | 127 | 147.9 | 177.9 | 216.5 |
| EBITDA | - | -225.3 | - | - | - | - | - | - |
| EBIT 1 | -210.7 | -228.2 | -217.8 | -174.7 | -110.6 | -15.4 | 3.088 | 36.57 |
| Operating Margin | -144.34% | -257.41% | -252.27% | -162.21% | -87.07% | -10.42% | 1.74% | 16.89% |
| Earnings before Tax (EBT) 1 | -204.7 | -227.3 | -220.7 | -182 | -110.6 | -14.29 | 1.417 | 39.5 |
| Net income 1 | -204.7 | -227.3 | -220.7 | -182 | -110.6 | -14.29 | 1.417 | 39.5 |
| Net margin | -140.27% | -256.41% | -255.58% | -169.05% | -87.02% | -9.66% | 0.8% | 18.24% |
| EPS 2 | -2.500 | -2.500 | -2.240 | -1.670 | -0.8000 | -0.0900 | 0.006670 | 0.2400 |
| Free Cash Flow 1 | -131.7 | -191.6 | -206.4 | -148.7 | - | -32.8 | -6.1 | 29 |
| FCF margin | -90.25% | -216.2% | -239.01% | -138.14% | - | -22.18% | -3.43% | 13.39% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 73.42% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/2/20 | 2/24/21 | 2/28/22 | 3/23/23 | 3/12/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 20.66 | 23.46 | 27.63 | 26.56 | 30.03 | 29.62 | 31.76 | 31.43 | 34.23 | 34.67 | 35.89 | 36.92 | 40.38 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -53.54 | -62.92 | -49.5 | -41.88 | -20.36 | -33.06 | -42.4 | -24.93 | -10.22 | -4.798 | -5.242 | -4 | -1.369 |
| Operating Margin | -259.2% | -268.25% | -179.15% | -157.71% | -67.79% | -111.64% | -133.5% | -79.31% | -29.85% | -13.84% | -14.61% | -10.83% | -3.39% |
| Earnings before Tax (EBT) 1 | -54.65 | -63.89 | -56.36 | -41.91 | -19.87 | -32.77 | -42.06 | -25.01 | -10.72 | -3.16 | -5.3 | -3.9 | -1.5 |
| Net income 1 | -54.65 | -63.89 | -56.36 | -41.91 | -19.87 | -32.77 | -42.06 | -25.01 | -10.72 | -3.16 | -5.3 | -3.9 | -1.5 |
| Net margin | -264.57% | -272.36% | -203.98% | -157.8% | -66.17% | -110.65% | -132.42% | -79.56% | -31.33% | -9.11% | -14.77% | -10.56% | -3.72% |
| EPS 2 | -0.5400 | -0.6300 | -0.5500 | -0.3800 | -0.1700 | -0.2700 | -0.3500 | -0.1700 | -0.0700 | -0.0200 | -0.0367 | -0.0267 | -0.006670 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/28/22 | 5/9/22 | 8/9/22 | 11/8/22 | 3/23/23 | 5/11/23 | 8/14/23 | 11/14/23 | 3/12/24 | 5/7/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -132 | -192 | -206 | -149 | - | -32.8 | -6.1 | 29 |
| ROE (net income / shareholders' equity) | -52.9% | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | -1.520 | - | - | - | - | - | - | - |
| Capex 1 | 7.15 | 6.81 | 3.02 | 1.83 | - | 3 | 3 | 3 |
| Capex / Sales | 4.9% | 7.69% | 3.5% | 1.69% | - | 2.03% | 1.69% | 1.39% |
| Announcement Date | 3/2/20 | 2/24/21 | 2/28/22 | 3/23/23 | 3/12/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.44
USD
Average target price
6.75
USD
Spread / Average Target
+96.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +102.35% | 512M | |
| +44.48% | 54.04B | |
| +43.57% | 41.96B | |
| -0.86% | 41.92B | |
| -7.59% | 28.35B | |
| +12.30% | 26.35B | |
| -21.83% | 19B | |
| +7.15% | 13B | |
| +29.40% | 12.28B | |
| +25.15% | 12.19B |
- Stock Market
- Equities
- HRTX Stock
- Financials Heron Therapeutics, Inc.
